Literature DB >> 27230483

Alexithymia in Parkinson's disease: a point of view on current evidence.

Alberto Costa1,2, Carlo Caltagirone2,3.   

Abstract

The risk of alexithymia in individuals with Parkinson's disease (PD) is about double compared with that observed in the general population. This finding indicates that alexithymia may be a relevant phenomenon in PD. However, several issues have to be clarified. The review here proposed outlines two main points. First, available data do not allow the clarification of whether alexithymia is independently associated with PD or if it is secondary to other mood and/or cognitive disorders. Second, it is not well understood how PD-related neurobiological changes may account for alexithymic expression. Our examination of extant literature also evidenced some potential limits of current tools and designs used that should carefully taken into account in further investigations of above issues.

Entities:  

Keywords:  Alexithymia; Parkinson's disease; affective disorders; neurobiological processes; neuropsychological deficits

Mesh:

Year:  2016        PMID: 27230483     DOI: 10.2217/nmt-2016-0001

Source DB:  PubMed          Journal:  Neurodegener Dis Manag        ISSN: 1758-2024


  3 in total

1.  Alexithymia, depression, and cognition in patients with Parkinson's disease.

Authors:  Gulay Kenangil; Mehmet Demir; Esma Tur; Fusun Domac
Journal:  Acta Neurol Belg       Date:  2021-01-16       Impact factor: 2.396

2.  Emotional cues from expressive behavior of women and men with Parkinson's disease.

Authors:  Shu-Mei Wang; Linda Tickle-Degnen
Journal:  PLoS One       Date:  2018-07-02       Impact factor: 3.240

3.  Augmentation in restless legs syndrome: an eye tracking study on emotion processing.

Authors:  Philipp Ellmerer; Beatrice Heim; Ambra Stefani; Marina Peball; Mario Werkmann; Evi Holzknecht; Melanie Bergmann; Elisabeth Brandauer; Martin Sojer; Laura Zamarian; Margarete Delazer; Klaus Seppi; Birgit Högl; Werner Poewe; Atbin Djamshidian
Journal:  Ann Clin Transl Neurol       Date:  2020-08-12       Impact factor: 4.511

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.